Page 1

EX - 99.1 2 exhibit991q32021earningspr.htm EX - 99.1 E OFEM BIOSCIENCE SⓇ Exhibit 99.1 Evofem Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Update -- Over 19,000 Phexxi TRx in Q3 2021 , a 48 % increase over Q2 2021-- -- 10,700 Phexxi NRx and over 13,600 TRx in the six weeks following the celebrity DTC campaign launch , up 94 % and 81 % , respectively , vs. preceding six - week period -- -- -- - More than 10,000 healthcare providers have prescribed Phexxi since launch -- - Company expects to reduce operating expenses by approximately $ 50 million in 2022 - -- Conference call scheduled for 4:30 p.m. ET Today -- SAN DIEGO , November 15 , 2021 - Evofem Biosciences , Inc. , ( NASDAQ : EVFM ) ( " Evofem " or the " Company " ) , today reported financial results for the three- and nine - month periods ended September 30 , 2021 . " We are extremely excited by the initial results of our celebrity DTC campaign , which is driving an increase in awareness of Phexxi among our target audience and substantial growth in prescriptions filled , " said Saundra Pelletier , Evofem's Chief Executive Officer . “ As we continue to reach more women who have had similarly negative experiences with hormonal contraception , it remains our priority to ensure that all women have access to Phexxi as a non - hormonal birth control option . " " We have achieved the goal of the first phase of our marketing strategy , to build a strong foundation of Phexxi prescribers and users . With the maturity of our marketing approach , we expect to reduce operating expenses by approximately $ 50 million in 2022 , ” concluded Pelletier . Third quarter and recent highlights include : • . • • Launched " House Rules , " our national direct - to - consumer ( DTC ) campaign with celebrity spokeswoman Annie Murphy aimed at broadening awareness and driving uptake of our hormone - free contraceptive , Phexxi® ( lactic acid , citric acid and potassium bitartrate ) vaginal gel . 94 % increase in new prescriptions , 81 % increase in total prescriptions and 82 % increase in dispensed units of Phexxi in the six weeks after " House Rules " launched , versus the preceding six week period . More than 19,000 Phexxi prescriptions were filled and more than 21,000 units were dispensed to patients during the third quarter of 2021 , an increase of 48 % and 44 % , respectively , compared to the second quarter of 2021 . Over 10,000 healthcare providers have prescribed Phexxi to date , reflecting ongoing growth in the prescriber base .